{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05712889",
            "orgStudyIdInfo": {
                "id": "VNC-236-101"
            },
            "organization": {
                "fullName": "Vincerx Pharma, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer",
            "officialTitle": "An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "phase-dose-escalation-study-for-in-patients-with-advanced-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-25",
            "studyFirstSubmitQcDate": "2023-01-25",
            "studyFirstPostDateStruct": {
                "date": "2023-02-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vincerx Pharma, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer",
            "detailedDescription": "All comers solid tumor subjects with histologically confirmed advanced or metastatic disease who have relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies."
        },
        "conditionsModule": {
            "conditions": [
                "Neoplasms"
            ],
            "keywords": [
                "VIP236",
                "Solid tumors",
                "All comers",
                "Breast cancer",
                "Small cell lung cancer",
                "Triple negative breast cancer",
                "Colorectal cancer",
                "Gastric cancer",
                "Lung cancer",
                "Non-small cell lung cancer",
                "Renal cancer",
                "Colon cancer",
                "Advanced solid tumors",
                "Metastatic cancer",
                "Bladder cancer",
                "Head and neck cancer",
                "Esophageal cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation of VIP236",
                    "type": "EXPERIMENTAL",
                    "description": "Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer",
                    "interventionNames": [
                        "Drug: VIP236"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VIP236",
                    "description": "VIP236 will be administered by IV infusion once every 3 weeks.",
                    "armGroupLabels": [
                        "Dose Escalation of VIP236"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of DLT (Dose limit toxicity) of VIP236",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days"
                },
                {
                    "measure": "Number of participants with adverse events as a measure safety and tolerability",
                    "timeFrame": "Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 21 days (up to approximately 10 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Disease control rate (DCR) per RECIST v1.1, defined as best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by Investigator review.",
                    "timeFrame": "Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 21 days (up to approximately 10 months)"
                },
                {
                    "measure": "Progression-free survival per RECIST v1.1, defined as the time from enrollment to documented disease progression or death from any cause, whichever occurs earlier as determined by Investigator review",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP236",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days"
                },
                {
                    "measure": "Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP236",
                    "timeFrame": "Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients aged \\>/=18 years, able to provide informed consent and willing to comply with all study procedures.\n* Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.\n* Adequate bone marrow, liver, and renal functions.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n\nExclusion Criteria:\n\n* Subjects who have new or progressive brain or meningeal or spinal metastases.\n* Clinically significant cardiac disease including congestive heart failure \\> New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.\n* Major surgery or significant trauma within 4 weeks before the first dose of study drug.\n* Medical history of chronic obstructive pulmonary disease (COPD) and other respiratory disorders.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vincerx Clinical Trials Contact",
                    "role": "CONTACT",
                    "phone": "1-650-800-6676",
                    "email": "clinicaltrials@vincerx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Vincerx Study Director",
                    "affiliation": "Vincerx Pharma, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Honor Health",
                    "status": "RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85258",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "NEXT Austin",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "NEXT Oncology San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Research Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Macquarie University",
                    "status": "RECRUITING",
                    "city": "Macquarie Park",
                    "state": "New South Wales",
                    "zip": "2109",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Research Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.7751,
                        "lon": 151.11272
                    }
                },
                {
                    "facility": "ICON Brisbane",
                    "status": "RECRUITING",
                    "city": "Brisbane",
                    "state": "Queensland",
                    "zip": "4101",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Research Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.46794,
                        "lon": 153.02809
                    }
                },
                {
                    "facility": "ICON Adelaide",
                    "status": "RECRUITING",
                    "city": "Adelaide",
                    "state": "Southern Australia",
                    "zip": "5037",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Research Site",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M10703",
                    "name": "Kidney Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "T120",
                    "name": "Cola",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}